Mannkind Corp (MNKD)
$1.56 0.06 (3.70%)
19:44 EST MNKD Stock Quote Delayed 15 Minutes
Previous Close $1.56
Market Cap 226.73M
PE Ratio -1.29
Volume (Avg. Vol.) 4.42M
Day's Range 1.51 - 1.66
52-Week Range 1.02 - 2.34
Dividend & Yield N/A (N/A)
MNKD Stock Predictions, Articles, and Mannkind Corp News
- From InvestorPlace
- From the Web
Signs are pointing to potential big gains for penny stocks in the coming days. These 5 dollars stocks are worth owning now.
Look to low-priced biotech stocks for some big-time bargains. Here are five great ones to buy today.
MannKind scored a collaboration deal with biotechnology giant, United Therapeutics. This development partnership could pay off big.
MNKD stock collapsed after disastrously poor Q2 earnings, but the real story is that MannKind now faces a bankruptcy threat.
MannKind Corporation (MNKD) stock was sliding after the bell following the company's quarterly earnings report, which included a year-over-year Afrezza revenue growth of 142%.
With a depressed share price, sales set to double this year, and a traditionally high-growth sector, it can be tempting to view MannKind Corp. (MNKD) as a bargain. Don’t make that mistake.
Volatility has send MannKind stock's options prices through the roof. You could sell option premium here, but is MNDK worth the risk?
The Sell recommendation for Mannkind Corp is the outcome of an analytical process that is proprietary which generated conclusions that were above average in 2 areas: an economic sector rated above average in attractiveness, and a mathematical computation of risk/reward that is better than average; and produced below average results in 4 areas: an industry group rated below average in attractiveness, a ranking in the company's sector that is in the middle third, ranking in the company's industry group that is in the middle third-below average, and analytical scoring that is well below average.
Small-cap stocks with strong earnings growth and down-to-earth valuations are performing better than even the largest of blue chips.
MannKind (MNKD) options soar on Afrezza label win, Apple (AAPL) is plagued by iPhone 8 battery bloating, while Netflix (NFLX) raised prices.
MannKind (MNKD) stock was up on Tuesday despite the company reporting an earnings and revenue miss in its second quarter of 2017.
These nine companies are either on the brink of Chapter 11 or already in bankruptcy proceedings. Either way, things look grim.
Just days after announcing a breakthrough distribution pact, MNKD delivered news of smaller first-quarter losses.
MannKind (MNKD) stock is still on the rise following the announcement of its deal with One Drop and speculation of a sale.
MannKind Corporation (MNKD) shares are down as the company approved a reverse split that will reduce from 700 million to 140 million shares.
MannKind (MNKD), down 90% over the past couple of years, is still fighting an uphill, un-winnable battle. MNKD stock is nearly out of time.
Thursday’s Vital Data: Apple Inc. (AAPL), Micron Technology, Inc. (MU) and MannKind Corporation (MNKD)
Wall Street yawns at Apple (AAPL) iPhone event, Micron (MU) rides DRAM projections and MannKind (MNKD) options bet big on Mylan (MYL) EpiPen rival.
MannKind (MNKD) is in the early stages of developing an inhalable form of epinephrine, which could help it take market share from the injectable version.
From Market News Video
Investors in MannKind Corp (MNKD) saw new options become available this week, for the March 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MNKD options chain for the new March 20th contracts and identified one put and one call contract of particular interest.
From Simply Wall St
Some stocks are best avoided. We really hate to see fellow investors lose their hard-earned money. For example, we sympathize with anyone who was caught holding MannKind Corporation (NASDAQ:MNKD) during<div><a class="permalink" href="https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mnkd/mannkind/news/imagine-owning-mannkind-nasdaqmnkd-and-taking-a-96-loss-square-on-the-chin/">Read More...</a></div>
Navellier RatingsPowered by Portfolio Grader